MX2024000116A - Agentes farmacologicos para prevenir y tratar cataratas y enfermedades oculares de presbicia. - Google Patents
Agentes farmacologicos para prevenir y tratar cataratas y enfermedades oculares de presbicia.Info
- Publication number
- MX2024000116A MX2024000116A MX2024000116A MX2024000116A MX2024000116A MX 2024000116 A MX2024000116 A MX 2024000116A MX 2024000116 A MX2024000116 A MX 2024000116A MX 2024000116 A MX2024000116 A MX 2024000116A MX 2024000116 A MX2024000116 A MX 2024000116A
- Authority
- MX
- Mexico
- Prior art keywords
- prevent
- eye diseases
- pharmacological agents
- subject
- cataracts
- Prior art date
Links
- 208000002177 Cataract Diseases 0.000 title abstract 2
- 201000010041 presbyopia Diseases 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010071690 Prealbumin Proteins 0.000 abstract 1
- 208000024777 Prion disease Diseases 0.000 abstract 1
- 102000009190 Transthyretin Human genes 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000016653 cleft lip/palate Diseases 0.000 abstract 1
- 208000002169 ectodermal dysplasia Diseases 0.000 abstract 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215818P | 2021-06-28 | 2021-06-28 | |
| PCT/US2022/035336 WO2023278464A1 (en) | 2021-06-28 | 2022-06-28 | Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000116A true MX2024000116A (es) | 2024-06-19 |
Family
ID=84692077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000116A MX2024000116A (es) | 2021-06-28 | 2022-06-28 | Agentes farmacologicos para prevenir y tratar cataratas y enfermedades oculares de presbicia. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240327439A1 (https=) |
| EP (1) | EP4362923A4 (https=) |
| JP (1) | JP2024524433A (https=) |
| CN (2) | CN116963727A (https=) |
| CA (1) | CA3225704A1 (https=) |
| MX (1) | MX2024000116A (https=) |
| WO (1) | WO2023278464A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872236B2 (en) | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| EP4243798A4 (en) * | 2020-11-13 | 2024-08-21 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID19540A (id) * | 1997-01-22 | 1998-07-23 | Hoffmann La Roche | Metode pembuatan turunan-turunan benzofenon |
| US20010044584A1 (en) * | 1997-08-28 | 2001-11-22 | Kensey Kenneth R. | In vivo delivery methods and compositions |
| KR20060013632A (ko) * | 2002-05-17 | 2006-02-13 | 오쎄라 파마슈티걸즈, 인크. | 백내장 및 다른 안질환 발병의 개선 |
| WO2014164667A1 (en) * | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| WO2018036498A1 (en) * | 2016-08-24 | 2018-03-01 | National Institute Of Biological Sciences, Beijing | Entacapone-related compounds to treat macular degeneration |
| US11872236B2 (en) * | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| KR20230021002A (ko) * | 2020-06-09 | 2023-02-13 | 에이에스엠엘 홀딩 엔.브이. | 내장 동축 조명부를 갖는 리소그래피 사전-정렬 이미징 센서 |
| EP4243798A4 (en) * | 2020-11-13 | 2024-08-21 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES |
-
2021
- 2021-11-15 CN CN202180090238.6A patent/CN116963727A/zh active Pending
-
2022
- 2022-06-28 CA CA3225704A patent/CA3225704A1/en active Pending
- 2022-06-28 MX MX2024000116A patent/MX2024000116A/es unknown
- 2022-06-28 CN CN202280058201.XA patent/CN117915900A/zh active Pending
- 2022-06-28 US US18/575,218 patent/US20240327439A1/en active Pending
- 2022-06-28 JP JP2023580804A patent/JP2024524433A/ja active Pending
- 2022-06-28 WO PCT/US2022/035336 patent/WO2023278464A1/en not_active Ceased
- 2022-06-28 EP EP22834075.8A patent/EP4362923A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023278464A1 (en) | 2023-01-05 |
| US20240327439A1 (en) | 2024-10-03 |
| CN116963727A (zh) | 2023-10-27 |
| CA3225704A1 (en) | 2023-01-05 |
| JP2024524433A (ja) | 2024-07-05 |
| EP4362923A4 (en) | 2025-03-19 |
| EP4362923A1 (en) | 2024-05-08 |
| CN117915900A (zh) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000116A (es) | Agentes farmacologicos para prevenir y tratar cataratas y enfermedades oculares de presbicia. | |
| CL2021001288A1 (es) | Heterociclos funcionalizados como agentes antivirales | |
| PE20250114A1 (es) | Compuestos indol sustituidos y metodos de uso de los mismos | |
| CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| CO5580771A2 (es) | Antagonistas ccr5 como agentes terapeuticos | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| SV2009002925A (es) | Derivados de oxadiazol | |
| AR033147A1 (es) | Compuestos de amida. | |
| CL2024003258A1 (es) | Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para tratar dolor | |
| AR035651A1 (es) | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion | |
| PE20081781A1 (es) | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos | |
| CO2024000054A2 (es) | Forma cristalina de tolebrutinib y método de preparación y su uso | |
| BR112022016131A2 (pt) | Compostos para tratamento de infecção por coronavírus | |
| PA8475401A1 (es) | Compuestos de sulfonilbenceno como agentes antiinflamatorios/analgesicos | |
| MX2022002839A (es) | Nuevo compuesto heterocíclico aromático tricíclico, método de preparación del mismo, composición farmacéutica y aplicación del mismo. | |
| AR014964A1 (es) | Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones | |
| CL2025001155A1 (es) | Compuestos 2,4,6-trisustituidos 1,3,5-triazinas moduladores de cx3cr1. | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| ES2177543T3 (es) | Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. | |
| EA200870090A1 (ru) | Применение производных сульфамида, включающих гетероцикл, конденсированный с бензольным кольцом, для лечения депрессии | |
| CO2025002028A2 (es) | Derivados novedosos de indol sulfonamida 7 sustituidos | |
| AR043253A1 (es) | 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. |